Also listed on Velicept Therapeutics, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Oct 19, 2031 · High confidence
20-year base term ends Aug 2, 2031
Aug 2, 2011
Oct 19, 2031
Feb 4, 2014
This patent's term runs 78 days past its 20-year base term on prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Aug 2, 2011, when this application, 13/196,068, was filed | Aug 2, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +78 days, USPTO patent term adjustment record | Oct 19, 2031 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,522,129) | resolves to Oct 19, 2031, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Oct 19, 2031 | High confidence |
This family
| US 8,642,661 | this patent Oct 2031 | Oct 2031 |
| US 9,522,129 | In force Oct 2031 | Oct 2031 |
| Application PCT/US2015/038583 | PCT application no patent term | no patent term |
| Application 15/235,720 | Abandoned not computed | not computed |
| US 9,907,767 | In force Aug 2031 | Aug 2031 |
| US 10,350,182 | In force Aug 2031 | Aug 2031 |
| US 10,668,034 | In force Aug 2031 | Aug 2031 |
| Application 16/839,710 | Abandoned not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Oct 13, 2011 Reel 27055, frame 757 | Caltabiano, Stephen; Ohlstein, Eliot; McCallum, Stewart | Altherx, Inc. | Assignment of Assignor's Interest |
| Sep 2, 2016 Reel 39621, frame 163 | Altherx, Inc. | Velicept Therapeutics, Inc. | Assignment of Assignor's Interest |
| Oct 7, 2019 Reel 50642, frame 74 | Velicept Therapeutics, Inc. | Oxford Finance LLC, as Collateral Agent | Security Interest |
| May 19, 2021 Reel 56285, frame 273 | Velicept (Assignment for the Benefit of Creditors), LLC; Velicept Therapeutics, Inc. | B3AR Therapeutics, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 9,522,129, ends no earlier than this term, so it caps nothing.